10月9日，哈门那盘后上涨12.11%，股价报433.99美元，成交额699.3万美元。本次异动主要由Cantor Fitzgerald将公司评级从观望上调至增持并设定460美元目标价所驱动。
该评级上调发生在公司近期经历了一轮股价回撤之后，此前哈门那在7月底发布二季度财报后因全年调整后每股收益指引仅维持至少9美元不变、缺乏上修动力而遭遇抛售。此后多家机构陆续上调评级或目标价，包括Evercore ISI、Leerink Partners、BofA Securities及Barclays等，其中Barclays在9月下旬将目标价从407美元大幅上调至515美元，推动股价单日上涨5.7%。Cantor Fitzgerald此次给出的460美元目标价高于FactSet统计的市场平均目标价432.12美元，显示其对公司盈利前景更具信心。
哈门那是一家总部位于肯塔基州路易斯维尔的大型医疗健康企业，业务涵盖保险与医疗服务，主要服务联邦医保、医疗补助参保者以及军人群体，其收入很大一部分来自联邦政府合同，尤其是医疗保险优势计划。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.